Danica Pension Livsforsikringsaktieselskab Makes New $27.83 Million Investment in Elevance Health, Inc. $ELV

Posted by Stanley Muller on Aug 19th, 2026

Danica Pension Livsforsikringsaktieselskab bought a new stake in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 71,955 shares of the company’s stock, valued at approximately $27,827,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. WealthCollab LLC lifted its holdings in Elevance Health by 42.2% in the first quarter. WealthCollab LLC now owns 91 shares of the company’s stock worth $27,000 after buying an additional 27 shares during the period. Signet Financial Management LLC grew its holdings in shares of Elevance Health by 3.5% during the 1st quarter. Signet Financial Management LLC now owns 837 shares of the company’s stock worth $245,000 after acquiring an additional 28 shares during the period. Sapient Capital LLC raised its position in shares of Elevance Health by 1.2% in the 1st quarter. Sapient Capital LLC now owns 2,612 shares of the company’s stock worth $765,000 after acquiring an additional 31 shares in the last quarter. Mutual Advisors LLC raised its position in shares of Elevance Health by 1.4% in the 4th quarter. Mutual Advisors LLC now owns 2,290 shares of the company’s stock worth $803,000 after acquiring an additional 32 shares in the last quarter. Finally, Waddell & Associates LLC lifted its stake in shares of Elevance Health by 2.6% in the 4th quarter. Waddell & Associates LLC now owns 1,241 shares of the company’s stock valued at $435,000 after purchasing an additional 32 shares during the period. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Up 2.3%

NYSE:ELV opened at $399.35 on Wednesday. The company’s 50 day moving average price is $394.99 and its 200-day moving average price is $358.90. Elevance Health, Inc. has a 52 week low of $274.84 and a 52 week high of $436.24. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.68. The stock has a market cap of $86.61 billion, a price-to-earnings ratio of 17.75, a PEG ratio of 2.30 and a beta of 0.68.

Elevance Health (NYSE:ELV – Get Free Report) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, topping analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. The company had revenue of $49.83 billion during the quarter, compared to analyst estimates of $48.88 billion. During the same period in the previous year, the business earned $8.84 EPS. The firm’s revenue for the quarter was up .8% on a year-over-year basis. On average, equities research analysts forecast that Elevance Health, Inc. will post 27.07 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Thursday, September 10th will be issued a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Thursday, September 10th. Elevance Health’s dividend payout ratio is presently 30.58%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ELV shares. Leerink Partners upped their price target on Elevance Health from $364.00 to $395.00 and gave the stock a “market perform” rating in a research note on Friday, July 17th. Citigroup raised Elevance Health to a “buy” rating in a research report on Wednesday, April 29th. Cantor Fitzgerald boosted their target price on shares of Elevance Health from $400.00 to $450.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Robert W. Baird upped their target price on shares of Elevance Health from $331.00 to $393.00 and gave the stock a “neutral” rating in a research report on Thursday, July 16th. Finally, TD Cowen increased their price target on shares of Elevance Health from $400.00 to $465.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, Elevance Health currently has a consensus rating of “Moderate Buy” and an average target price of $440.90.

View Our Latest Stock Report on ELV

Insider Activity

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the sale, the director directly owned 10,734 shares of the company’s stock, valued at $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.34% of the stock is currently owned by insiders.

Elevance Health Profile

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.